32 C
Vientiane
Sunday, June 8, 2025
spot_img
Home Blog Page 2104

OnePlus Confirms Launch Date for its Next Flagship Products

Bringing new smartphone OnePlus 11 5G, earbuds OnePlus Buds Pro 2, and more to the fore.

NEW DELHI, INDIA – Media OutReach – 19 December 2022 – Global technology brand OnePlus announced today that The OnePlus Cloud 11 launch event will take place on February 7, 2023, in New Delhi, India. Themed “Cloud 11” to represent the upgraded technology and performance delivered by the brand’s latest products, the event focuses on an ensemble of OnePlus flagship products that elevate user experience from “Cloud 9” to “Cloud 11”. It will kickstart the year with a hopeful outlook for tech enthusiasts and OnePlus’ community of loyal users.

ONEPLUS-SALAMI.jpg

The Powerful Duo: Introducing the OnePlus 11 5G and the OnePlus Buds Pro 2

During the event, various OnePlus products will be making their debut, but the highlight remains to be the official unveiling of two new flagship devices, the OnePlus 11 5G and the OnePlus Buds Pro 2.

This flagship smartphone is set to take the brand’s fast and smooth experience to new heights. The OnePlus 11 5G marks the return of two user-favorite features – the sophisticated Hasselblad imaging that makes photos true to life, and the handy Alert Slider that makes it easy to shift from mode to mode.

OnePlus has also designed the ideal companion to the OnePlus 11 5G – the OnePlus Buds Pro 2, which promises to deliver a full-bodied, stereo-quality audio experience with crystal clarity.

The announcement of the OnePlus 11 5G and the OnePlus Buds Pro 2 serves as a testament that OnePlus continues to move forward and reach upward. “We’re thrilled to be revealing these exciting new products that bring a levelled up fast and smooth experience to the market,” said Pete Lau, Founder of OnePlus, Senior Vice President and Chief of Product at OPPO and OnePlus. “The OnePlus 11 5G, the OnePlus Buds Pro 2, and other products are driven by our community co-creation spirit and will be equipped with the most advanced technology to provide a refined experience to our users.”

Hashtag: #OnePlus

The issuer is solely responsible for the content of this announcement.

About OnePlus

OnePlus is a global mobile technology brand that challenges conventional concepts of technology. Founded on the “Never Settle” mantra, OnePlus creates exquisitely designed devices with premium build quality and high-performance hardware. OnePlus thrives on cultivating strong bonds and growing alongside its community of users and fans.

For more information, please visit OnePlus.com or follow us on:
Instagram –
Facebook –
Twitter –
LinkedIn –
YouTube –
TikTok –

The Miss Universe Organization and Mouawad unveil “The Crown Number 12: Force for Good ” in Thailand.

BANGKOK, THAILAND – Media OutReach – 19 December 2022 – The Miss Universe Organization today unveiled “The Crown Number 12: Force for Good”, crafted by world-renowned luxury jeweler Mouawad. The new crown, with pear-shaped blue sapphires surrounded by diamonds and valued at approximately USD 5.58 million, will be the prestigious mark of honor for the winner of the 71st MISS UNIVERSE® Competition. The event will take place on January 14, 2023, in New Orleans, Louisiana, United States.

PressReleaseTMPatlApH.jpg

A unique, bespoke work of art and craft, the Force for Good crown emanates Mouawad’s passion for crafting the extraordinary, featuring the meticulous setting of sapphires and diamonds, whose design is replete with symbolism. Reflecting the point that significant change does not happen in an instant, the base of the crown is set with diamonds symbolizing the status quo. From the base upwards, rippling wave motifs reflect the momentum of change, with their varying sizes portraying that this momentum gains ground gradually through advocacy at different moments and places, to audiences large and small, over time.

“It has been an honor to craft a new crown for The Miss Universe Organization, and to create a new sparkling chapter in the story of Mouawad Miss Universe crowns, said Mouawad Co-guardian Fred Mouawad. “The Mouawad Miss Universe Force for Good Crown is a work of extraordinary craftsmanship, completely crafted and set and by hand total 993 stones setting, featuring 110.83 carat of blue sapphire and 48.24 carat of white diamond in a design that evokes The Miss Universe Organization’s belief in a future forged by women who push the limits of what’s possible and the incredible women from around the world who advocate for positive change.”

Upon closer inspection, the culmination of these wave-like curls at the base emulates a serpent’s head, symbolizing the challenges involved in swaying opponents and those with a vested interest in maintaining the status quo. As the eye moves upward from the base of the crown, the color gradient changes from the glistening white of diamonds to the warm blue of sapphires, deepening in intensity toward the pinnacle of the crown. At the top, a stunning of Royal Blue sapphire pear-shape 45.14 carat displays a depth of color emblematic of the goodness that can be achieved through persistent action and of the hope for a brighter future.

Anne Jakapong Jakrajutatip, Chief Executive Officer of JKN Global Group Public Company Limited, as the new owner of The Miss Universe Organization, said: “The Miss Universe 2022 Force for Good Crown stands for a graceful reincarnation of The Miss Universe Organization’s long-standing values and heritage as a guiding light, shining bright to the future glory. The new crown is also the dazzling illustration of both the challenges and rewards that come when young women advocate for causes close to their heart and strive make an impact on the world.”

As we are stepping into the new era of women’s empowerment, The Miss Universe Organization will continue to be a global organization run by women for women with a promise to serve as an inspirational platform that celebrates diverse women, supporting them to realize their ambition and build self-confidence, while evolving the brand over time to be more relevant and appealing to the next generation. Our new ambition is to instill the sense of passion for ‘transformational leadership’ among us all, with firm belief that everyone can lead, to be successful and achieve their life goals. With this future-oriented approach, the Miss Universe brand is keen to take on a pivotal role in involving and engaging people on a journey toward social inclusion, gender equality and environmental sustainability,” added Anne Jakapong.

The “MISS UNIVERSE x MOUAWAD: Unveiling the new crown “Force for Good”, the New Emblem of Beautifully Confident” press conference revealed the new crown held in TRUE ICON HALL, 7th floor, ICONSIAM. Bangkok, Thailand, and has been witnessed by over 150 local media and VIPs. The event was also broadcast via JKN 18 TV channel and live streaming on Miss Universe YouTube channel and JKN18 Facebook page, attended by thousands of international media.

The partnership between The Miss Universe Organization and Mouawad was formed in 2019, which saw winners of a prestigious competition, MISS UNIVERSE® honored with crowns crafted by Mouawad.

Anne Jakapong Jakrajutatip said she was excited to bring the new crown to the stage of the 71st MISS UNIVERSE® Competition herself. The event will take place on Saturday, January 14, 2023, at the New Orleans Ernest N. Morial Convention Center, New Orleans, Louisiana, United States. Last year’s winner Miss India Harnaaz Sandhu will crown her successor at the end of the event.

Hashtag: #TheMissUniverseOrganization #MOUAWAD

The issuer is solely responsible for the content of this announcement.

Lao Airlines Plane Clipped by Korean Jet at Incheon Airport

Lao Airlines hit by Air Premia jet at Incheon Airport.
Lao Airlines hit by Air Premia jet at Incheon Airport (Photo: Yonhap News)

A Lao Airlines passenger aircraft collided with another plane at Incheon International Airport early today, however, no injuries were reported.

Laos Commits to Zero Greenhouse Gas Emissions by 2025

Greenhouse gas emissions.

The government of Laos expressed its commitment to achieving zero greenhouse gas emissions by 2025 during the recent session of the National Assembly.

Luxury beauty advisory SWISS REJU wins COSMOPOLITAN Best of the Best Panel’s Choice Award, celebrating exceptional body contouring results

HONG KONG SAR – Media Outreach – 19 December 2022 – Luxury beauty advisory SWISS REJU has been honored with “Best of the Best Panel’s Choice Award” by prestigious beauty giant COSMOPOLITAN. This award is an affirmation of SWISS REJU’s innovative body contouring program and its outstanding effects on helping people to obtain better body shape safely and non-invasively.

-73A1665.jpg

“We are very delighted to receive this prestigious award from COSMOPOLITAN, it is such an honor to take part in this year’s event. This win is also a big recognition of our efforts and commitment to leading the future of body contouring. This is only made possible by the dedication of our associates, guests and technology partners,” says the spokesperson of SWISS REJU.

COSMOPOLITAN Best of the Best Awards are well recognized in the world of luxury beauty. The awards celebrate exceptional beauty products and services which have demonstrated effectiveness and innovation. Each year, the selection committee objectively evaluates and carefully hand picks innovative new offerings that make a difference to the industry.

“High end beauty and body contouring market has always been very competitive, this win is an excellent encouragement to our team.” says the spokesperson of SWISS REJU.

SWISS REJU’s proprietary technology K-Lipolysis is an innovative body contouring program that allows customers to comfortably shape their body, without the risks and discomfort of traditional liposuction surgeries. Harnessing the exclusive technology of laser, electromagnetic field and other innovative energy modalities, SWISS REJU K-Lipolysis makes it easier to obtain a better body shape with technology.

“We once again thank the panel judges and expert editors at COSMOPOLITAN for this wonderful award. We will continue to invest in new technology so more clients can get to experience the benefits of modern body contouring.”

Learn more about SWISS REJU: http://www.reju.hk

Hashtag: #SwissREJU

The issuer is solely responsible for the content of this announcement.

LOCA launches LOCA PAY Enabling QR Code payment via Credit Card

Loca launched a new product “Loca Pay” on 16 December 2022, with a new goal to be a convenient and safe digital payment intermediary for everyone.

Hong Kong Baptist University develops new aptamer drug for bone anabolic therapies

HONG KONG SAR – Media OutReach – 19 December 2022 – A research team led by Hong Kong Baptist University (HKBU) has identified a molecular target for bone anabolic therapies using a selected aptamer that serves as an inhibitor of sclerostin, a protein that prevents bone growth. The discovery offers hope for the development of an effective next-generation treatment for osteoporosis and osteogenesis imperfecta that is free of cardiovascular risk compared to the marketed antibody drug.

(From left) Dr Yu Yuanyuan, Professor Lyu Aiping, Professor Zhang Ge, and Dr Wang Luyao, Post-Doctoral Research Fellow of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU, develop the new aptamer drug for osteoporosis and osteogenesis imperfecta.
(From left) Dr Yu Yuanyuan, Professor Lyu Aiping, Professor Zhang Ge, and Dr Wang Luyao, Post-Doctoral Research Fellow of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU, develop the new aptamer drug for osteoporosis and osteogenesis imperfecta.

The research findings have been published in the international academic journals Nature Communications and Theranostics. The New drug is at the pre-clinical trial development stage, and the research team plans to start clinical trials in the US and on the Mainland in 2024.

Current medication increases cardiovascular risk

Osteoporosis is a metabolic condition which leads to a reduction in bone density, resulting in weakened bones that are more fragile and likely to break. Osteogenesis imperfecta, also known as “brittle bone disease”, is a rare congenital genetic disorder characterised by extremely fragile bones. Sclerostin has been identified as a therapeutic target for both diseases.

In 2019, the US Food and Drug Administration (FDA) approved the use of the monoclonal antibody against sclerostin for the treatment of postmenopausal osteoporosis. Studies have also shown that sclerostin antibody enhances bone mass and bone strength of mice with osteogenesis imperfecta. However, as sclerostin plays a protective role in the cardiovascular system, it was seen that sclerostin antibody increased the risk of heart attacks, stroke and cardiovascular death during clinical trials. Therefore, a black box warning for potential cardiovascular risks is required by FDA.

A research team led by Professor Lyu Aiping, Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicineand Director of the Institute of Integrated Bioinformedicine and Translational Science at HKBU; Professor Zhang Ge, Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU; and Dr Yu Yuanyuan, Manager of the Guangdong-Hong Kong-Macau Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery and Assistant Professor of the School of Chinese Medicine at HKBU, endeavoured to develop alternative drug options.

“loop3” identified as a new therapeutic target

Sclerostin suppresses bone formation by antagonising the “Wnt signalling pathway”. The “Wnt signalling pathway” modulates the stem cells responsible for skeletal tissue regeneration. Therefore, inhibition of sclerostin promotes bone growth.

The research team discovered that a “loop3 domain” in the core region of sclerostin can be used as a molecular target to inhibit sclerostin. Through genetic studies, it was shown that deficiency of the loop3 domain can inhibit sclerostin’s antagonistic effect against the Wnt signalling pathway, but it does not affect the cardiovascular protective effect of sclerostin. The result suggests that the loop3 domain can serve as a molecular target for inhibiting sclerostin while preserving its cardiovascular protective function.

The researchers then proceeded to screen aptamers that can specifically inhibit sclerostin loop3. Aptamers are single-stranded DNA or RNA molecules that can selectively bind to molecular targets such as proteins. After binding with specific proteins, aptamers may inhibit protein–protein interactions and thereby elicit certain therapeutic effects. Through a combinatorial technology, an aptamer “aptscl56” was selected as a potential sclerostin inhibitor that targets the loop3 structure.

Aptamer selected as effective and safe sclerostin inhibitor

The research team examined aptscl56’s therapeutic functions with osteoporotic rat models and osteogenesis imperfecta mouse models. They found that aptscl56 effectively promots bone formation. On the other hand, the application of aptscl56 does not increase the risk of developing cardiovascular diseases such as aortic aneurysms and atherosclerotic development in both models.

The medical use of aptamers confers certain advantages, such as thermal stability and ease of synthesis. However, they are prone to rapid degradation and renal filtration. The research team therefore modified aptscl56 to produce an aptamer named “Apc001” with a longer half-life. The team demonstrated that Apc001 promotes bone formation, increases bone mass, improves bone microarchitecture integrity, and enhances bone mechanical properties in rats with osteoporosis and mice with osteogenesis imperfecta.

Clinical trials due to start in 2024

“Searching for reliable and safe alternatives to overcome the limitations of the currently available drugs is crucial to help patients who need bone anabolic therapies. Our ongoing studies, which span from identifying molecular targets for sclerostin inhibition to aptamer drug discovery, offer hope for the development of next-generation sclerostin inhibitors in the near future,” said Professor Zhang Ge.

“Our search for alternative drugs for bone anabolic therapies is a good example of tripartite collaboration between academia, industry and the government. The research work was partly conducted in collaboration with a local biotechnology company, and it was supported by the Innovation and Technology Fund. Some biotechnology companies in the Mainland were engaged in certain aspects of developmental research for the aptamer, such as toxicology tests. The collaborative efforts will continue to create more synergy and fruitful results,” said Professor Lyu Aiping.

The therapeutic aptamer Apc001 was granted orphan drug designation by the FDA for the treatment of osteogenesis imperfecta in 2019.

Hashtag: #HongKongBaptistUniversity #HKBU

The issuer is solely responsible for the content of this announcement.

Straw Hut Village is New Tourist Attraction in Vientiane Province

People gather and enjoy themselves at a straw hut | (Photo: ເມືອງເຟືອງແດນງາມ Mueng Fueng Dan Ngam)

Straw Hut Village, a new tourist attraction just opened this month in Vientiane Province’s Meuang Feuang district, to attract both domestic and international visitors.